Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pfizer partners with startup Flagship valued at US$7 Billion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 18, 2023 12:29pm

173 Views

Post# 35546244

RE:RE:RE:RE:Pfizer partners with startup Flagship valued at US$7 Billion

Partnerships are formed around early stage companies. ONCY is a late stage Phase 3-ready bio-platform company whose platform addresses multiple cancers with unmet treatment needs, like the kind of potential high-value assets that Big Pharma companies are seeking to acquire given their need to address their looming patent cliffs and replenishment of their product portfolios, that are specifically targeting biologicals in the immuno-oncology market space.

<< Previous

Bullboard Posts

Next >>

ArcStone-Kingswood Growth Summit 2024: A premier growth conference